NCT06094231View on ClinicalTrials.gov

Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

September 30, 2025

Conditions
Chronic Kidney DiseasesDiabetes MellitusPreDiabetesOverweight and Obesity
Interventions
BEHAVIORAL

Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor

The patients will be educated on how to implement a therapeutic carbohydrate restriction, which consists of 50 to 130 grams of carbohydrate per day, simultaneously they will continue to receive the SGLT-2-Inhibitor dapagliflozin.

Trial Locations (1)

1160

RECRUITING

6th Medical Department with Nephrology and Dialysis, Clinik Ottakring, Vienna

All Listed Sponsors
lead

Department of Nephrology Clinic Ottakring Vienna

OTHER